ArticleEuropean journal of medicinal chemistry2026
3H-pyrazolo[4,3-f]quinoline hinge binder, a tunable scaffold for development of novel kinase inhibitors against FLT3-driven leukemia.
Article in European journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The 3H-pyrazolo[4,3-f]quinoline moiety, synthesized via a Doebner or Povarov multi-component reaction, has been described as an innovative scaffold capable of interacting with the hinge region of several protein kinases, including FLT3. The receptor tyrosine kinase FLT3 and its oncogenic variants, such as ITD or D835Y, has been validated as a therapeutic target for the therapy of acute myelogenous leukemia. In this study, we demonstrate that the substitution pattern of the phenyl group at the 7-posititon of 3H-pyrazolo[4,3-f]quinoline has an impact on FLT3 kinase inhibition. Out of 48 synthesized compounds, we present here HSB401, which showed nanomolar inhibitory activities against recombinant FLT3-ITD, FLT-ITD-F691L and D835Y mutants and FLT3-driven cancer cell lines MOLM-13 and MV4-11, as well as Ba/F3 cells associated with the FLT3-ITD mutation. Approved FLT3 inhibitor quizartinib strongly inhibits both FLT3 and c-KIT, resulting in significant myelosuppression. Notably, the lead compound HSB401 inhibits c-KIT with approximately 100-fold lower potency compared to FLT3-D835Y. This suggests that HSB401 may spare normal hematopoiesis and mitigate the risk of myelosuppression. Mechanistic studies in MV4-11 cells revealed downregulated FLT3 signaling after 2 h of treatment with HSB401 and cell cycle arrest and apoptosis in the prolonged experiment. In addition, oral administration of HSB401 significantly suppressed tumor growth in the MV4-11 xenograft mouse model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.